Temozolomide for high grade glioma

Area of Science:

• Neuro-oncology
• Clinical trials
• Pharmacotherapy

Background:

• High-grade glioma (HGG) is an aggressive brain tumor.
• Standard treatment includes surgery and radiotherapy.
• Temozolomide is an oral chemotherapy agent with brain penetration and low adverse effects.

Purpose of the Study:

• To evaluate the efficacy of temozolomide compared to conventional therapy for HGG.
• To assess temozolomide's benefit in both primary and recurrent disease settings.

Main Methods:

• Systematic review of randomized controlled trials (RCTs).
• Searched multiple databases including Cochrane, Medline, and EMBASE.
• Included patients of all ages with pathologically diagnosed HGG.

Main Results:

• In primary Glioblastoma Multiforme (GBM), temozolomide significantly increased survival (HR 0.84) and time to progression (HR 0.52) without negatively impacting quality of life.
• Early adverse events were low, with 5-14% Grade 3/4 hematological toxicity.
• In recurrent GBM, temozolomide improved time to progression (HR 0.68) but not overall survival, with low severe adverse events.

Conclusions:

• Temozolomide is effective in primary GBM for prolonging survival and delaying progression with minimal impact on quality of life and low early adverse events.
• Late adverse event data for temozolomide is currently unknown.
• Temozolomide improves time to progression in recurrent GBM but not overall survival.